Search
for
Sort by
Research 781–810 of 1000+
- Baricitinib Effectiveness in JAKi‐Naïve and Tofacitinib‐Exposed Patients: A Prospective Study in Alopecia Areata
- Case Report: Successful Treatment of Alopecia Universalis With Tofacitinib and Increased Cytokine Levels: Normal Therapeutic Reaction or Danger Signal?
- JAK inhibition decreases the autoimmune burden in Down syndrome
- Merkel cell carcinoma: updates in tumor biology, emerging therapies, and preclinical models
- JAK inhibition decreases the autoimmune burden in Down syndrome
- Immunosenescence and inflammaging in Parkinson’s disease: mechanisms and therapeutic prospects
- A Patient Preference-Weighted Quantitative Benefit-Risk Analysis of Ritlecitinib for Alopecia Areata to Inform Medical Decision Making
- Central nervous system demyelination associated with tofacitinib use in alopecia areata: A case report and literature review
- Exploring novel management options for alopecia areata
- Short-term Efficacy of Tofacitinib, a JAK Inhibitor, in IFIH1-related Aicardi-Goutières Syndrome
- Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells
- The influence of interferon on healthy and diseased skin
- The role of Janus kinase inhibitors in the treatment of alopecia areata: A systematic review
- Application of Baricitinib in Dermatology
- Off-Label Uses of Abrocitinib: Review of Emerging Therapeutic Applications beyond Atopic Dermatitis
- Xinyang tablet ameliorates sepsis-induced myocardial dysfunction by regulating Beclin-1 to mediate macrophage autophagy and M2 polarization through LncSICRNT1 targeting E3 ubiquitin ligase TRAF6
- Baricitinib-loaded separable microneedle array patch (S-MAP) based on hyaluronic acid for alopecia areata therapy
- Janus kinase inhibitors for alopecia areata: A narrative review
- Ritlecitinib for the Management of Alopecia Areata: A Narrative Review of Real-World Evidence and Selected Post Hoc Analyses
- Evaluating the Causal Relationship Between Human Blood Metabolites and the Susceptibility to Alopecia Areata
- Topical Delivery of Tofacitinib in Dermatology: The Promise of a Novel Therapeutic Class Using Biodegradable Dendritic Polyglycerol Sulfates
- Tyrosine kinase Inhibitors in Dermatology: A Systemic Review
- JAK-Inhibitors Beyond the Label: Emerging Applications in Dermatology
- Systemic Inflammation Marker Alterations in Severe Alopecia Areata Patients Treated with Janus Kinase Inhibitors
- Defining a Therapeutic Window of Opportunity in Alopecia Areata: Predictors of Early Response to Baricitinib
- A systematic review of tumor necrosis factor-α blockers, anti-interleukins, and small molecule inhibitors for dissecting cellulitis of the scalp treatment
- Hair follicle targeting via gelatin coated transferosomes loaded with tofacitinib citrate for enhanced treatment of alopecia areata: Clinical evaluation of alopecia areata patients
- Predictive factors for treatment responses to baricitinib in severe alopecia areata: A retrospective, multivariate analysis of 70 cases from a single center
- Efficacy and Safety of Baricitinib in Patients With Alopecia Areata: A Real‐World Cohort Study
- Discovery of a novel and highly selective JAK3 inhibitor as a potent hair growth promoter